April 26, 2006 -- SuperGen said an interim analysis of a Phase II trial of its cancer drug showed that the compound was not beneficial; CV Therapeutics reported a sharply higher loss because of marketing costs for recently approved Ranexa; Vertex Pharma fell on a bigger loss; Celera will soon announce a genetic test for hepatitis C patients, showing which ones are likely to develop liver problems; NPS Pharma received European approval for its osteoporosis drug; Inspire Pharma will begin a Phase II trial of its antiplatelet drug; Spectrum and GPC Biotech said the data monitoring board recommended continuing the Phase III trial of its prostate cancer compound; BioMimetic set the terms for its upcoming IPO; LeMaitre Vascular made its initial IPO filing; and Bayer and Onyx said Nexavar has been given orphan drug status by the FDA for liver cancer. The Centient Biotech 200™ was down 44 points at 3714.18, a loss of 1.18%. More details...
